Armed T cells
Armed-T cells represent an engineered approach to T cell-based research, using bispecific antibodies to redirect T cells toward specific target cells. These antibody constructs act as molecular bridges, facilitating proximity between T cells and their intended targets. This strategy is being investigated for its potential to enhance immune-cell engagement and specificity in preclinical models.
What are Armed-T cells?
Armed-T cells are T cells modified to engage specific targets using bispecific antibodies that act as a molecular bridge between the T cell and the antigen- presenting cell. This platform concept builds on the clinical success of FDA-approved bispecifics, such as Blincyto® (blinatumomab), used in B-cell acute lymphoblastic leukemia (B-ALL).
Armed-T strategies represent a promising area of immunotherapy research, enabling targeted immune redirection without the need for genetic modification. As an active area of preclinical and clinical investigation, Armed-T cell approaches continue to evolve across both hematologic and solid tumor contexts.
Innovative Armed-T Therapy
by SL BIO
At SL BIO, we are proud to introduce Armed-T an advanced immunotherapy platform designed to explore precision T cell engagement using bispecific antibody technology. Licensed from CytoArm, a recognized innovator in immune redirection, Armed-T reflects our commitment to next-generation research and high development standards.
This approach supports ongoing efforts to develop targeted immune strategies for investigational applications in oncology.
Targeted Engagement Strategy
Armed-T technology is designed to help direct T cell interaction toward tumor- associated targets while aiming to reduce off-target activation. This approach is currently under preclinical investigation.
T Cell Activation Support
Through CD3 engagement, the platform is being explored for its potential to support immune cell activation in tumor model systems.
Licensed Innovation from CytoArm
Developed with CytoArm’s expertise in immune redirection, Armed-T reflects ongoing advancements in investigational immunotherapy platforms.
Patents
Publication
